Compare Moderna, Inc. (MRNA) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Moderna, Inc. trades at $59.72 (market cap $23.60B), while YieldMax TSLA Option Income Strategy ETF trades at $25.63. The key difference: Moderna, Inc. is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MRNA | TSLY | |
|---|---|---|
Market Cap | $23.60B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $81.80 | $48.25 |
52-Week Low | $22.36 | $25.07 |
Enterprise Value | $19.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
TSLY, the YieldMax TSLA Option Income Strategy ETF, trades at $25.07, down 2.57% today amid a bearish technical signal. The ETF generates high income through weekly distributions, with recent dividends ranging from $0.26 to $0.52 per share, but faces criticism for capping upside during Tesla rallies. Its strategy relies on synthetic Tesla exposure and covered call overlays, producing an annualized yield near 52.65%, though distributions are largely return of capital.
The outlook is cautious due to structural limitations that sacrifice capital appreciation for income, with risks including volatility from Tesla's performance and option strategy complexity. Investors prioritizing yield may find value, but those seeking growth could underperform Tesla's equity returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
